SI-BONE, Inc. - Common Stock (SIBN)

In a significant move to avert a potential financial crisis, the Federal Reserve announced in October 2025 its decision to halt its three-year Quantitative Tightening (QT) program and cut interest rates. This decisive action comes amidst growing concerns over tightening liquidity in money markets and recent market strains, signaling that

SI-BONE INC reports mixed Q2 2025 results with revenue slightly below estimates but beats on EPS, driving a positive market reaction. Strong growth and raised guidance signal confidence.

Four companies experienced significant short-term rallies following better-than-expected earnings; can they maintain momentum going forward?

SIBN stock results show that SI-BONE beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar.

SIBN stock results show that SI-BONE beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.